These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 25712185

  • 1. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
    Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H.
    Pharmacogenomics; 2015; 16(3):217-25. PubMed ID: 25712185
    [Abstract] [Full Text] [Related]

  • 2. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
    Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM, Wen MS, Scordo MG, Nutescu EA, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Takahashi H.
    Pharmacogenomics J; 2017 Dec; 17(6):494-500. PubMed ID: 27503578
    [Abstract] [Full Text] [Related]

  • 3. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
    Ohara M, Suzuki Y, Shinohara S, Gong IY, Schmerk CL, Tirona RG, Schwarz UI, Wen MS, Lee MTM, Mihara K, Nutescu EA, Perera MA, Cavallari LH, Kim RB, Takahashi H.
    Clin Pharmacokinet; 2019 Aug; 58(8):1077-1089. PubMed ID: 30815847
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [Abstract] [Full Text] [Related]

  • 9. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.
    Lancet; 2013 Aug 31; 382(9894):790-6. PubMed ID: 23755828
    [Abstract] [Full Text] [Related]

  • 10. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM.
    Blood; 2015 Jul 23; 126(4):539-45. PubMed ID: 26024874
    [Abstract] [Full Text] [Related]

  • 11. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
    Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.
    Pharmacogenomics; 2012 Mar 23; 13(4):407-18. PubMed ID: 22329724
    [Abstract] [Full Text] [Related]

  • 12. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
    Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.
    Clin Pharmacol Ther; 2011 Mar 23; 89(3):408-15. PubMed ID: 21270790
    [Abstract] [Full Text] [Related]

  • 13. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.
    Blood Cells Mol Dis; 2009 Mar 23; 43(1):119-28. PubMed ID: 19297219
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.
    Pediatr Blood Cancer; 2014 Jun 23; 61(6):1055-62. PubMed ID: 24474498
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF, Pengo V, Moz S, Bozzato D, Fogar P, Padoan A, Plebani M, Groppa F, De Rosa G, Padrini R.
    Eur J Clin Pharmacol; 2018 May 23; 74(5):571-582. PubMed ID: 29396738
    [Abstract] [Full Text] [Related]

  • 17. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
    Li X, Liu R, Yan H, Tang J, Yin JY, Mao XY, Yang F, Luo ZY, Tan SL, He H, Chen XP, Liu ZQ, Li Z, Zhou HH, Zhang W.
    J Clin Pharmacol; 2015 Mar 23; 55(3):251-7. PubMed ID: 25187307
    [Abstract] [Full Text] [Related]

  • 18. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA.
    Clin Pharmacol Ther; 2010 Apr 23; 87(4):459-64. PubMed ID: 20072124
    [Abstract] [Full Text] [Related]

  • 19. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
    Bargal SA, Kight JN, Augusto de Oliveira F, Shahin MH, Langaee T, Gong Y, Hamadeh IS, Cooper-DeHoff RM, Cavallari LH.
    Clin Transl Sci; 2021 Mar 23; 14(2):492-496. PubMed ID: 33278335
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.